Open main menu

Psychiatrienet β

Amisulpride-Lurasidone

Revision as of 13:37, 5 March 2015 by Roland (talk | contribs)
Amisulpride
Type Antipsychotic
Group Atypical AP
links
PubChem 2159
PubMed Amisulpride
Wikipedia Amisulpride
Lurasidone
Type Antipsychotic
Group Atypical AP
links
Medscape Lurasidone
PubMed Lurasidone
Kompas (Dutch) Lurasidone
Wikipedia Lurasidone

Switch medication from Amisulpride to Lurasidon.[1] [2]

Nietinrijdenbord.png Stop Amisulpride
  • Day 1-7: gradually reduce the dose of amisulpride to 50% of the dose.
  • Day 8-14: gradually reduce the dose of amisulpride to 0% of the dose
  • Day 14: stop administration of amisulpride.
Eenrichtingbord.png Start Lurasidon
  • Day 1-7: start administration of lurasidon in a dose of 40 mg/day.
  • Day 8-14: increase the dose of lurasidon to 80 mg/day if necessary. Note: Continue the dose of lurasidone 40 mg/day if the patiënt is stable.[3]
Infobord.png More information
  • During this switch you could monitor ECG, especially in patients prone to QT-conduction problems.
  • There is a possibility of QT interval prolongation.[4]
  1. ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. ↑ McEvoy JP et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.J Clin Psychiatry. 2013 Feb;74(2):170-9.
  4. ↑ Stöllberger C, Huber JO, Finsterer J, Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005 Sep;20(5):243-51.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
Retrieved from "https://wiki.psychiatrienet.nl/w/index.php?title=Amisulpride-Lurasidone&oldid=6910"